Comparative Effectiveness of Methotrexate versus Methylprednisolone in Treatment Naïve Pulmonary Sarcoidosis Patients

Among those who study granulomatous diseases, sarcoidosis is of tremendous interest, not only because its cause is unknown, but also because it is still as much an enigma today as it was 150 years ago when Jonathan Hutchinson first described the cutaneous form of the disease as “livid papillary psor...

Descripción completa

Detalles Bibliográficos
Autor principal: Pasipanodya, Jotam G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392209/
https://www.ncbi.nlm.nih.gov/pubmed/34441335
http://dx.doi.org/10.3390/diagnostics11081401
_version_ 1783743447607279616
author Pasipanodya, Jotam G.
author_facet Pasipanodya, Jotam G.
author_sort Pasipanodya, Jotam G.
collection PubMed
description Among those who study granulomatous diseases, sarcoidosis is of tremendous interest, not only because its cause is unknown, but also because it is still as much an enigma today as it was 150 years ago when Jonathan Hutchinson first described the cutaneous form of the disease as “livid papillary psoriasis”. This piece editorializes a comparative effectiveness study of methotrexate versus methylprednisolone in treatment naïve pulmonary sarcoidosis patients for CT-guided clinical responses and drug-related adverse events.
format Online
Article
Text
id pubmed-8392209
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83922092021-08-28 Comparative Effectiveness of Methotrexate versus Methylprednisolone in Treatment Naïve Pulmonary Sarcoidosis Patients Pasipanodya, Jotam G. Diagnostics (Basel) Commentary Among those who study granulomatous diseases, sarcoidosis is of tremendous interest, not only because its cause is unknown, but also because it is still as much an enigma today as it was 150 years ago when Jonathan Hutchinson first described the cutaneous form of the disease as “livid papillary psoriasis”. This piece editorializes a comparative effectiveness study of methotrexate versus methylprednisolone in treatment naïve pulmonary sarcoidosis patients for CT-guided clinical responses and drug-related adverse events. MDPI 2021-08-03 /pmc/articles/PMC8392209/ /pubmed/34441335 http://dx.doi.org/10.3390/diagnostics11081401 Text en © 2021 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Commentary
Pasipanodya, Jotam G.
Comparative Effectiveness of Methotrexate versus Methylprednisolone in Treatment Naïve Pulmonary Sarcoidosis Patients
title Comparative Effectiveness of Methotrexate versus Methylprednisolone in Treatment Naïve Pulmonary Sarcoidosis Patients
title_full Comparative Effectiveness of Methotrexate versus Methylprednisolone in Treatment Naïve Pulmonary Sarcoidosis Patients
title_fullStr Comparative Effectiveness of Methotrexate versus Methylprednisolone in Treatment Naïve Pulmonary Sarcoidosis Patients
title_full_unstemmed Comparative Effectiveness of Methotrexate versus Methylprednisolone in Treatment Naïve Pulmonary Sarcoidosis Patients
title_short Comparative Effectiveness of Methotrexate versus Methylprednisolone in Treatment Naïve Pulmonary Sarcoidosis Patients
title_sort comparative effectiveness of methotrexate versus methylprednisolone in treatment naïve pulmonary sarcoidosis patients
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392209/
https://www.ncbi.nlm.nih.gov/pubmed/34441335
http://dx.doi.org/10.3390/diagnostics11081401
work_keys_str_mv AT pasipanodyajotamg comparativeeffectivenessofmethotrexateversusmethylprednisoloneintreatmentnaivepulmonarysarcoidosispatients

Ejemplares similares